Analysis of GLP-1 Diabetes Treatment Drugs Market in China GLP-1 diabetes treatment drugs in China is projected to exhibit exceptional growth with a CAGR of 34.2% through 2035, driven by the rapidly expanding diabetes population and massive government investments in healthcare infrastructure development across major urban centers
Weight Loss Can Reduce Muscle Mass, Bone Density, and Metabolism Rapid weight loss, while beneficial in some aspects, can lead to decreased muscle mass, reduced bone density, and a lower metabolic rate, potentially causing sarcopenia
GLP-1 is rapidly degraded by an enzyme named dipeptidyl peptidase-IV (DPP-4), converting to bioinactive products GLP-1 (9-36) and GLP-1 (9-37) (13), which have a very low affinity for GLP-1 receptor (GLP-1R) and have no insulin secretion effect
Among the 388 subjects with type 2 diabetes mellitus treated in Study 2, reductions in HbA1c from baseline (6.8%) were 0.1% for placebo compared to 0.4% and 0.4% with QSYMIA 7.5 mg/46 mg and QSYMIA 15 mg/92 mg, respectively
Mitochondrial dysfunction As a dynamic biophysical system, mitochondria play a major role in regulating energy metabolism and dominating cell death or survival
